ArticleToxicology reports2025
Evaluation of the effects of dimethyl fumarate on transforming growth factor beta levels in the liver of rats with bile duct ligation-induced cholestasis.
Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cholestasis is a reduction or cessation of bile flow in the biliary system, which can be life-threatening. Dimethyl Fumarate could induce anti-inflammatory and antioxidant effects in the body. Objective: This investigation focused on assessing the impact of Dimethyl Fumarate on liver levels of transforming growth factor beta (TGF-β) to mitigate biochemical, histopathological, and immunohistochemical alterations in cholestasis-induced rat models. Methods: Forty male adult Wistar rats were divided into eight groups (healthy control treated with distilled water, healthy rats treated with 50, 100, and 200 mg/kg of Dimethyl Fumarate, bile duct ligation (BDL), and experiment BDL groups were treated with 50, 100, and 200 mg/kg of Dimethyl Fumarate). After the gavage treatment period of 45 days, the rats were anesthetized and underwent blood sampling. Liver damage was assessed by measuring hepatic marker enzymes (alanine transaminase, aspartate transaminase, alkaline phosphatase, gamma-glutamyl transferase, and total bilirubin), histopathological (lesion assessment), and immunohistochemical (TGF-β expression level) observation. Results: The findings demonstrated that administration of varying doses of Dimethyl Fumarate via gavage led to a statistically significant reduction in serum concentrations of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, and total bilirubin ( Conclusion: This strategy may reduce inflammation, cholestasis, and fibrosis outcomes, attributed to its anti-inflammatory and antioxidant properties. Nonetheless, further research is necessary to substantiate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.